×
European VC breaks taboo by investing in pure defense tech from Ukraine’s war zones | TechCrunch

European VC breaks taboo by investing in pure defense tech from Ukraine’s war zones | TechCrunch

Defense tech has gone from a no-go zone for VCs to a hot investment sector. However, dual use — meaning that the technology must also have civilian applications — is still a requirement for most of them, including the NATO Innovation Fund. 

Estonian VC firm Darkstar breaks from this trend by investing in purely military applications, with the goal of helping rearm Europe using combat-proven solutions emerging from Ukraine. “This is very critical, not only today but for the next 10 years,” said its cofounder and general partner Ragnar Sass (second from the left in the picture).

The firm takes a hands-on approach to this mission, helping startups bring products to military customers both in Ukraine and throughout Europe. For Ukrainian teams, this means not just funding but also support with setting up compliant entities in NATO countries like Estonia. “In any company which wants to be part of European procurement or even grants, the operational side has to be perfect,” Sass said. 

With a fundraising target of €25 million (approximately $29.2 million) in the next six to 12 months, Darkstar intends to focus on pre-seed and seed rounds, with a usual check size of €500k to €1 million. It has already made two investments: in Ukrainian-Estonian startups FarSight Vision, which specializes in geospatial analytics and 3D mapping for drone pilots, and Deftak, which develops ammunition for drones.

For Sass, investing in weapons wasn’t an obvious move. A key figure in the Estonian startup ecosystem ever since Skype’s founders funded his first startup, a community for pet owners, he went on to co-found CRM and sales tool Pipedrive, and used the proceeds of that unicorn-sized exit to make more than 50 angel investments.

Some of these investments became unicorns, too, including Veriff. But none of them were in defense, even after Russia’s full-scale invasion of Ukraine in 2022 prompted Sass to deliver trucks and aid to Ukraine, to which he has personal and business ties.

“It took quite a long time mentally to understand that I want to be involved in weapon systems,” Sass said. He eventually made his choice a year and a half ago when Estonian drone startup Krattworks became his first defense investment.

Krattworks marked a turning point for Sass; it was also his last investment as an angel investor. Sass is now putting his money into Darkstar, which started out as a coalition organizing hackathons and bootcamps, leveraging his decade-long experience at hackathon community Garage48 between 2010 and 2020. Since then, Sass went on to fund and sell another company, Salto X, although it is unclear whether he made money from that exit.

Sass isn’t the only one backing this approach. Fifteen-month-old Darkstar just completed a first close of €15 million (approximately $17.5 million) backed by European entrepreneurs, family offices, and Estonian state-backed LP SmartCap, TechCrunch learned exclusively.

Backing a fund like Darkstar makes SmartCap an exception as well, alongside Lithuania’s sovereign VC fund Coinvest Capital, which became authorized to make defense investments without requiring civilian use cases in 2023. It’s no coincidence that all of these come from the Baltics.

Russia’s proximity and the Soviet Union’s former occupation give Estonians like Sass a sense of urgency that is now spreading across Europe as investors recognize the importance of defense. “But if you don’t have real know-how in that area, you’re struggling,” Sass said. For Darkstar, building that know-how meant talking to end users from day one.

In Darkstar’s case, the end users are Ukraine’s brigades. While some changes are being implemented, the country has adopted a decentralized approach, enabling combat units to make their own decisions. This can be hard to navigate for outsiders, but Sass got a head start.

“In the last three and a half years, I have been to Ukraine 20-plus times, and I have personally met 100-plus unit commanders — spent time with them, talked with them, learned from them,” said the entrepreneur, who also found a lot of common ground. “Elite units are more similar to startups than we can imagine.”

Although cheap first-person view (FPV) drones have been used to destroy equipment worth millions, Sass says that it would be a huge mistake to think that tech developments from Ukraine are easily copyable. There’s sophistication — “most elite drone battalions in Ukraine have their own R&D” — and there is velocity on both sides of the frontline. For instance, fiber-optic drones have been a game changer.

For startups outside of Ukraine, it means that a solution that works on paper could become pointless, and that’s where Darkstar’s bootcamps are meant to help. The next one will take place this summer in Kyiv, and according to its website, will give companies “feedback, field-testing opportunities and combat validation.”

Some of Darkstar’s deal flow will come from its bootcamps, where staff work hands-on with teams for five days. But the pipeline is broader, and Ukraine’s 2,000 eligible teams stand out. “Many of the Ukrainian companies we are looking at are not six months old; they have been around two-plus years and they have already managed to build a product and company with minimum capital.”

General mobilization of Ukrainian men isn’t as big an obstacle as often assumed. Founders building effective combat products can receive exemptions and travel approval, and a significant percentage of Ukraine’s defense startup founders are women, including FarSight Vision CEO, Viktoriia Yaremchuk, Sass said. As for the restriction on defense tech exports out of Ukraine, that hurdle is in the process of being removed.

Darkstar GPs Kaspar Gering, Philip Jungen and Ragnar Sass with Farsight Vision CEO Viktoriia YaremchukImage Credits:Darkstar

Sass is applying a similar location philosophy to defense investing. Just as he once argued that “early-stage Nordic startups should cut the crap and move to Silicon Valley,” Darkstar won’t invest in companies that intend to stay based exclusively in Ukraine. It is also talking to teams based in Central and Eastern Europe, Latvia, the U.K. and Germany, among others. “After a year or two, this [portfolio] will be a way more diverse and mixed group.”

In alignment with this goal, Darkstar describes itself as pan-European in background. Sass is joined by Estonia-based GPs Kaspar Gering, who spent a decade at Wise in engineering and data science roles, and Mart Noorma, director of the NATO Cooperative Cyber Defence Centre of Excellence (on the left in the main picture). A fourth GP, Philip Jungen, is based in Germany, with another partner and additional staffers in Ukraine.

As for categories, Darkstar plans to invest in autonomous systems, air defense, electromagnetic warfare, communications, cybersecurity, sensors, as well as surveillance and intelligence, both with single and dual uses.

According to Sass, some of these could turn into acquisition targets for cash-rich prime contractors struggling to deliver the rapid solutions that NATO countries are now willing to buy from them. But fueled by governments coming to terms with how the war in Ukraine has transformed modern warfare, other startups could also reach hundreds of million in revenue on their own and even go public.

It is unclear whether defense startups, particularly those without civilian applications, can achieve breakout success on their own. However, the rapid rise and valuation of companies like Anduril and Helsing along with a wave of new defense-focused funds, suggests that the prospect of venture-scale returns is being taken more seriously.

Either way, what keeps Sass going is something bigger. Though he embraces the humor of NAFO, a global online movement leveraging memes to support Ukraine, Sass also delivers a sober warning about Russia’s relentless war economy. “The enemy is moving very fast, and that’s exactly why I believe that we need to have the tech community being involved way more to address that huge and growing threat.”

Source link
#European #breaks #taboo #investing #pure #defense #tech #Ukraines #war #zones #TechCrunch

officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.

Luna Band: Key Highlights

Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.

The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.

Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.

Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.

Price and Availability

Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026.

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna">Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.

Luna Band: Key Highlights

Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.

The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.

Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.

Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.

Price and Availability

Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026.

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna">Luna Introduces Luna Band With Real-Time Health Tracking Features

Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.

Luna Band: Key Highlights

Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.

The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.

Luna Introduces Luna Band With Real-Time Health Tracking Features
	
Luna has officially unveiled the Luna Band, a new voice-first wearable designed to help users improve their daily routines through real-time health tracking. Supported by the company’s LifeOS intelligence system, the wearable continuously monitors body signals and transforms them into personalized recommendations. Luna designed the device for people who want smarter support for productivity, recovery, and overall health. The invite-only Drop 1 is expected to begin shipping by the end of July 2026.



Luna Band: Key Highlights



Luna designed the Luna app to make health tracking simpler and more organized by consolidating several wellness features into a single platform. This app integrates features that involve stress management, nutrition, exercise, supplements, and recovery into a single application. Another customization option available to users is creating personal health modules in the app.



The application brings together aspects of stress, diet, fitness, nutritional supplements, and productivity within the app’s micro-apps. Users can also sync third-party devices and other relevant health-related data sources for a more personalized experience.







The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.



Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.



Price and Availability



Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026. 

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna

The company also allows users to create their own health modules in the app rather than relying solely on prebuilt features. Alongside this, Luna highlights its voice-logging feature, which eliminates the need for manual data entry. Users can quickly record meals, workouts, and daily habits through simple voice commands, making health tracking faster.

Luna designed LifeOS as one of its main AI-powered features to simplify health tracking through personalized insights and recommendations. The system continuously studies body signals, lifestyle habits, biomarkers, and health trends to deliver a better understanding of overall wellness. Luna says LifeOS is included with the Luna Band platform.

Price and Availability

Luna has confirmed that the first release of the Luna Band, called Drop 1, will be available through an invite-only system. Users interested in the wearable can sign up through the company’s official waitlist before shipping starts later in July 2026.

#Luna #Introduces #Luna #Band #RealTime #Health #Tracking #FeaturesLuna
suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As">Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As

that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As">Can Ozempic Treat Alcoholism? Here’s What You Should Know

Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders.

Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As

Post Comment